Axa S.A. Buys Shares of 9,200 Progyny, Inc. (NASDAQ:PGNY)

Axa S.A. bought a new stake in Progyny, Inc. (NASDAQ:PGNYGet Rating) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 9,200 shares of the company’s stock, valued at approximately $341,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new position in Progyny in the 1st quarter valued at about $62,000. Parkside Financial Bank & Trust acquired a new position in shares of Progyny in the 1st quarter worth approximately $70,000. Nisa Investment Advisors LLC lifted its holdings in shares of Progyny by 390.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,207 shares of the company’s stock worth $97,000 after acquiring an additional 1,757 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Progyny by 25.0% in the 1st quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock worth $107,000 after acquiring an additional 418 shares during the last quarter. Finally, Win Advisors Inc. acquired a new position in shares of Progyny in the 3rd quarter worth approximately $163,000. 86.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on PGNY. KeyCorp decreased their price objective on shares of Progyny from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Monday, December 19th. JPMorgan Chase & Co. decreased their price objective on shares of Progyny from $78.00 to $62.00 and set an “overweight” rating on the stock in a report on Friday, November 18th. Finally, SVB Leerink restated a “market perform” rating and issued a $34.00 price objective (down from $59.00) on shares of Progyny in a report on Thursday, January 5th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.25.

Insider Buying and Selling

In related news, CEO Peter Anevski sold 32,000 shares of the business’s stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $36.37, for a total transaction of $1,163,840.00. Following the completion of the transaction, the chief executive officer now directly owns 223,900 shares of the company’s stock, valued at approximately $8,143,243. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Norman Payson sold 6,617 shares of the company’s stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total transaction of $209,428.05. Following the completion of the transaction, the director now directly owns 279,063 shares of the company’s stock, valued at approximately $8,832,343.95. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Peter Anevski sold 32,000 shares of the company’s stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $36.37, for a total value of $1,163,840.00. Following the transaction, the chief executive officer now directly owns 223,900 shares of the company’s stock, valued at $8,143,243. The disclosure for this sale can be found here. Insiders sold 148,766 shares of company stock valued at $5,284,643 in the last three months. 14.00% of the stock is owned by corporate insiders.

Progyny Price Performance

PGNY opened at $38.23 on Thursday. Progyny, Inc. has a 12 month low of $25.67 and a 12 month high of $53.10. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of 127.43 and a beta of 1.59. The business has a fifty day moving average price of $32.57 and a 200 day moving average price of $36.27.

Progyny (NASDAQ:PGNYGet Rating) last released its earnings results on Monday, February 27th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.02 by $0.01. Progyny had a return on equity of 9.71% and a net margin of 3.86%. The firm had revenue of $214.32 million during the quarter, compared to analysts’ expectations of $211.78 million. During the same period in the previous year, the firm posted $0.15 EPS. Progyny’s revenue for the quarter was up 68.0% on a year-over-year basis. On average, research analysts anticipate that Progyny, Inc. will post 0.37 earnings per share for the current year.

Progyny Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Further Reading

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYGet Rating).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.